Ignite Creation Date:
2024-05-06 @ 7:27 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06015880
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-08-26
Brief Title:
Testing the Combination of Anti-cancer Drugs Mosunetuzumab Polatuzumab Vedotin and Lenalidomide for the Treatment of RelapsedRefractory Diffuse Large B-Cell Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
| Diffuse Large B-Cell Lymphoma Not Otherwise Specified |
| High Grade B-Cell Lymphoma |
Keywords: